Kedudukan dalam Saham
#25838
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Perubahan (1 hari)
-0.15%
Perubahan (1 tahun)
-6.28%
Perdagangan Mendus AB (publ) (IMMU)
Harga IMMU dengan permodalan pasaran b
Modal pasaran bagi Mendus AB (publ)(IMMU)
Modal Pasaran: $45.86M
Sehingga August 2026, Mendus AB (publ) mempunyai modal pasaran sebanyak $45.86M. Ini menjadikan Mendus AB (publ) syarikat ke-25838th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Mendus AB (publ) dari 2013 hingga 2026
IMMU berbanding dengan 5 teratas yang paling popular stocks
| Harga IMMU |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.257T
|
+11,462,312.92%
|
|
|
|
|
$4.599T
|
+10,027,128.07%
|
|
|
|
|
$4.107T
|
+8,954,186.11%
|
|
|
|
|
$3.577T
|
+7,799,997.77%
|
|
|
|
|
$2.807T
|
+6,121,148.29%
|
